AAN 2023
Highlights from the American Academy of Neurology 2023 Annual Meeting, April 22 - 27, 2023.
Valbenazine induces global improvements and psychiatric stability in tardive dyskinesia
Presenter: Andrew Cutler, MD, SUNY Upstate Medical University, Syracuse, NY
A post-hoc analysis of clinical trial data shows that long-term treatment with once-daily valbenazine is effective for managing TD symptoms while maintaining patients’ psychiatric well-being.
Endovascular thrombectomy improves medical care outcomes for large ischemic strokes
Presenter: Amrou Sarraj, MD, University of Texas Health Science Center at Houston, Houston, TX
Among patients with large ischemic strokes, endovascular thrombectomy results in better functional outcomes than medical management.
Lecanemab reduces clinical decline in early Alzheimer’s disease
Presenter: Christopher van Dyck, MD, Yale School of Medicine, New Haven, CT
Lecanemab produced moderate declines on measures of cognition and function at 18 months in patients with early Alzheimer disease.
Future therapies on near horizon for Huntington disease
Presenter: Jee Bang, MD, Johns Hopkins Medicine, Baltimore, MD
Gene-based therapies, NMDA-receptor modulators, and a vesicular monoamine transporter are being investigated for Huntington disease.
Zavegepant nasal spray safe and effective treatment for acute migraine
Presenter: Richard B. Lipton, MD, Albert Einstein College of Medicine, Bronx, NY
In a phase III trial, zavegepant nasal spray produced rapid onset of relief and sustained benefit for the acute treatment of migraine with minimal side effects.
Valbenazine decreases disease burden in patients with chorea associated with Huntington disease
Presenter: Dietrich Haubenberger, MD, Neurocrine Biosciences, San Diego, CA
Valbenazine can reduce Huntington disease-related burden according to patient-reported outcomes.
Spinal cord stimulation provides pain relief in diabetic neuropathy
Presenter: Erika Petersen, MD, University of Arkansas in Little Rock, AK
High-frequency spinal cord stimulation provides pain relief for patients with painful diabetic neuropathy.
Treatment of functional movement disorders should be patient-centered
Presenter: David L. Perez, MD, of Harvard Medical School, Boston, MA
The patient is the agent of change in functional movement disorders and must be included in the treatment team.
Blepharoclonus serves as a potential novel clinical marker in Parkinson disease
Presenter: Nestor Beltre, MD, Department of Neurology, University of Miami Miller School of Medicine, Miami, FL.
Blepharoclonus may be a novel clinical marker in Parkinson Disease.